Administration (FDA): the Premarket Approval Application and the Premarket Notification, trough the 510k Clearances. The 510k pathway is less stringent, as the new device should have roughly the same characteristics to the "predicate device" that the new one is being compared. As little or no clinical evidence is required prior to market entry, safety concerns were reported for some devices in different areas. The FDA recalls medical devices posing safety risks. Our purpose is to analyze devices cleared by the 510k and FDA's recall database in uro-oncology over the last 4 years.
INTRODUCTION AND OBJECTIVES: Overprescription of narcotics after surgery contributes significantly to the ongoing opioid crisis. Therefore, interventions to minimize the quantity of pills prescribed postoperatively are timely and critical. We assessed perioperative and post-discharge narcotic utilization to identify factors associated with low or no home opiate use.
METHODS: Patients prospectively recorded their home pain pill usage on a pain pill log, including narcotics, acetaminophen, and ibuprofen, following robotic radical prostatectomy (RP) and robotic partial nephrectomy (PN) at 2 academic institutions. At the first postop visit, clinic staff counted remaining narcotic pills to verify reported narcotic utilization. We extracted data on in-hospital pain medication use (measured in morphine equivalents), pain score on POD1, and patient comorbidities from electronic medical records. We applied multivariate logistic and linear regression to identify factors associated with no postoperative pill use and degree of pill use.
RESULTS: A total of 117 RP and 47 PN patients had complete data and were included in the study. Patients were prescribed 5-30 oxycodone pills at time of discharge. For RP patients, 52% of patients took 0 pills after discharge, and 91% took 10 or fewer pills. If 5 pills were prescribed, 82% of patients would not require a narcotic refill postoperatively. Patients using fewer perioperative narcotics and with lower pain scores on day of discharge used fewer pills after discharge. On multivariate analysis controlling for age, chronic pain, and baseline alcohol and drug use, each additional perioperative morphine equivalent use was associated with an OR of 0. CONCLUSIONS: Most patients take few, or zero, prescribed narcotics after robotic urologic surgery. Patients with low postop pain scores, and who take few narcotics while in-hospital, may not need narcotic prescriptions for discharge. Clinicians should utilize these parameters to aid in limiting numbers of prescribed but unused pills.
Source of Funding: None

MP10-03 DOES ATTENDING SURGEON TIME SPENT IN THE OPERATING ROOM INFLUENCE PERIOPERATIVE OUTCOMES AND VARIABLE COST?
INTRODUCTION AND OBJECTIVES: The total time the attending surgeon (AS) is present in the operating room (OR) during a surgical case may impact patient outcomes and overall cost. Current literature supports senior surgical trainees independently performing procedures with equivalent outcomes. The aim of this study is to determine if the time the AS spends in the OR during minimally invasive surgery (MIS) urological procedures correlates with peri-operative outcomes and variable cost.
METHODS: Our prospectively collated institutional review board approved database and the institutional financial accounting system were used to identify all patients undergoing six common MIS urological procedures during the 2016-2017 fiscal year. The time the AS spent in the OR for each case was prospectively collected and converted into the percentage of time from first incision to closure of skin. The patient cohort was divided into two groups based on the median time the AS spent in the OR for each procedure type: the lower group (LG) and the upper group (UG). The primary outcome of interest was operating time (OT) and total variable cost. Secondary outcomes included length of stay (LOS), estimated blood loss (EBL) and prostatectomy T2 positive surgical margins (PSMs).
RESULTS: A total of 804 MIS procedures were identified. Overall, the median percentage time the AS was present in the OR was 77% (Table 1 ). The ASA, variable cost ($12,382 v $12,431, p[0.97) Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
